TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32554854

Group type: EXPERIMENTAL
Intervention: Long-chain and very long-chain acylcarnitines
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Odd-chain acylcarnitines
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Eicosadienoylcarnitine
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Hydroxystearoylcarnitine
Number of subjects: 163
Study: 32554922

Group type: EXPERIMENTAL
Intervention: Deep-learning model (neural network)
Number of subjects: 8980

Group type: COMPARATOR
Intervention: Traditional spirometry metrics (FEV1/FVC)
Number of subjects: 8980

Group type: COMPARATOR
Intervention: Traditional spirometry metrics (FEV1% predicted)
Number of subjects: 8980

Group type: COMPARATOR
Intervention: Random forest classifier
Number of subjects: 8980
Study: 32554923

Group type: EXPERIMENTAL
Intervention: Complement inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 32555070

Group type: EXPERIMENTAL
Intervention: Mindful movement treatment (8-week program, 2 classes per week for 60 minutes)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Mindful movement treatment
Number of subjects: 34
Study: 32555385

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32555582

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32555630

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg (6-9 injections)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg (2-5 injections)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg (1 injection)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg (baseline VA <23 letters)
Number of subjects: 405
Study: 32556247

Group type: EXPERIMENTAL
Intervention: TanCAR7 T cells
Number of subjects: 33
Study: 32556281

Group type: EXPERIMENTAL
Intervention: IV pembrolizumab 10 mg/kg every 2 weeks for up to 2 years or until confirmed progression or unacceptable toxicity
Number of subjects: 31
Study: 32556286

Group type: EXPERIMENTAL
Intervention: Whole transcriptome sequencing of single hematopoietic stem and progenitor cells from patients with GATA2 deficiency
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Computational imputation of cells with chromosomal abnormalities
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Analysis of cells with complex cytogenetic abnormalities
Number of subjects: 8
Study: 32556328

Group type: EXPERIMENTAL
Intervention: COVID-19 symptoms in seniors
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Patients aged ≥80 years
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Patients with neurocognitive disorders
Number of subjects: 353
Study: 32556473

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 141
Study: 32556623

Group type: EXPERIMENTAL
Intervention: Subjective assessment using Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Objective assessment using ActiGraph accelerometer
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Comparison of PSQI and ActiGraph measures
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Total sleep time comparison
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Identification of sleep parameters
Number of subjects: 54
Study: 32556682

Group type: EXPERIMENTAL
Intervention: High-dose stereotactic body radiation therapy (SBRT)
Number of subjects: 52
Study: 32556731

Group type: EXPERIMENTAL
Intervention: Cytoreduction, gastrectomy, and HIPEC with 30 mg mitomycin C and 200 mg cisplatin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cytoreduction, gastrectomy, and HIPEC
Number of subjects: 20
Study: 32556819

Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy during EGD
Number of subjects: 37956

Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy during colonoscopy
Number of subjects: 37956

Group type: COMPARATOR
Intervention: No antithrombotic therapy during EGD
Number of subjects: 37956

Group type: COMPARATOR
Intervention: No antithrombotic therapy during colonoscopy
Number of subjects: 37956
Study: 32556843

Group type: EXPERIMENTAL
Intervention: Anterior ultrasonography approach for postoperative vocal cord edema
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Novel lateral ultrasonography approach for postoperative vocal cord edema
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Anterior ultrasonography approach for vocal cord paralysis
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Novel lateral ultrasonography approach for vocal cord paralysis
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Overall incidence of vocal cord paralysis
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Risk factors for vocal cord paralysis
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Diagnostic accuracy of the novel lateral approach
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Diagnostic accuracy of the anterior approach
Number of subjects: 90
Study: 32557093

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 383

Group type: COMPARATOR
Intervention: Ticagrelor
Number of subjects: 383
Study: 32557168

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injections (2.0 mg) administered using a fixed dosing regimen during the first year and a treat-and-extend treatment regimen during the second year.
Number of subjects: 50
Study: 32557382

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg weekly for up to 148 weeks
Number of subjects: 2677
Study: 32557394

Group type: EXPERIMENTAL
Intervention: Tiotropium/Olodaterol fixed-dose combination (FDC) administered for 6 weeks
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Tiotropium/Olodaterol fixed-dose combination (FDC)
Number of subjects: 309
Study: 32557558

Group type: EXPERIMENTAL
Intervention: PACK-CXL with standard antibiotic therapy
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard antibiotic therapy alone
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: PACK-CXL with standard therapy
Number of subjects: 59
Study: 32557715

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32557834

Group type: EXPERIMENTAL
Intervention: Immunomodulatory treatment
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: APAH
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Stool microbiome analysis
Number of subjects: 45
Study: 32557976

Group type: EXPERIMENTAL
Intervention: Next-generation sequencing (NGS) in plasma
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Matched targeted agents for patients with druggable alterations
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: NGS in tissue
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 235
Study: 32558205

Group type: EXPERIMENTAL
Intervention: Post-exposure prophylaxis (PEP) regimens, including Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) as the preferred backbone (n=14,304; 74%)
Number of subjects: 29060
Study: 32558260

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Elevated ethmoid-to-maxillary (E/M) ratio
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Elevated E/M ratio
Number of subjects: 165
Study: 32558402

Group type: EXPERIMENTAL
Intervention: Open-label ganaxolone (225 mg twice daily, increased to 450 mg twice daily if tolerated) administered for 8 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Open-label ganaxolone
Number of subjects: 10
Study: 32558407

Group type: EXPERIMENTAL
Intervention: Escitalopram monotherapy (10-20 mg daily for 8 weeks)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Aripiprazole augmentation (2-10 mg daily for 8 weeks)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Escitalopram monotherapy
Number of subjects: 188
Study: 32558525

Group type: EXPERIMENTAL
Intervention: EndoAnchors
Number of subjects: 43
Study: 32558692

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS) implantation after scoring balloon (SCB) predilation
Number of subjects: 220

Group type: COMPARATOR
Intervention: Conventional BVS implantation
Number of subjects: 220
Study: 32558897

Group type: EXPERIMENTAL
Intervention: Vaccination with irradiated, CpG-activated tumor cells followed by reinfusion of vaccine-primed lymphocytes after ASCT
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Vaccination with irradiated, CpG-activated tumor cells
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High tumor PD-L1 expression after in vitro exposure to CpG
Number of subjects: 45
Study: 32559194

Group type: EXPERIMENTAL
Intervention: Machine learning models using multi-omics and clinical data
Number of subjects: 3029

Group type: EXPERIMENTAL
Intervention: Clinical model with 9 clinically accessible variables
Number of subjects: 3029

Group type: EXPERIMENTAL
Intervention: Combination of omics and clinical variables
Number of subjects: 3029
Study: 32559419

Group type: EXPERIMENTAL
Intervention: Therapeutic blockade of granulocyte macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 32559465

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32560151

Group type: EXPERIMENTAL
Intervention: Short-term myocardial temporal dispersion ECG variables
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: QT end (QTe), QT peak (QTp), T peak to T end (Te)
Number of subjects: 113
Study: 32561087

Group type: EXPERIMENTAL
Intervention: Preoperative portal embolization (PVE) plus administration of CD133 + cells mobilized from peripheral blood with G-CSF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Portal embolization (PVE) only
Number of subjects: 0
Study: 32561439

Group type: EXPERIMENTAL
Intervention: Bronchoscopy under general anesthesia with RP-EBUS and fluoroscopic guidance
Number of subjects: 57
Study: 32561474

Group type: EXPERIMENTAL
Intervention: Non-technical skills (NTS)
Number of subjects: 20
Study: 32561512

Group type: EXPERIMENTAL
Intervention: Gait speed derived from a 6 minute walking test (6MWT) before hospital discharge.
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Gait speed <0.7 m/s (slow walkers).
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Gait speed ≥0.7 m/s (non-slow walkers).
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Gait speed as a predictive variable.
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Gait speed in a multivariate model adjusted for age, gender, BMI, forced expired volume, heart failure, and home mechanical ventilation.
Number of subjects: 71
Study: 32561664

Group type: EXPERIMENTAL
Intervention: Tislelizumab (200 mg i.v. Q3W) plus chemotherapy (cisplatin and fluorouracil for ESCC; oxaliplatin and capecitabine for G/GEJ)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tislelizumab plus chemotherapy
Number of subjects: 30
Study: 32561908

Group type: EXPERIMENTAL
Intervention: NAFLD (HFF ≥5.5%)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: PNPLA3 rs738409 and Gemmiger
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: PNPLA3 rs738409 and Oscillospira
Number of subjects: 73
Study: 32561912

Group type: EXPERIMENTAL
Intervention: Filarial antigen stimulation in mf-positive patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Filarial antigen stimulation in all patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of cytokine production between mf-positive and mf-negative patients
Number of subjects: 0
Study: 32561964

Group type: EXPERIMENTAL
Intervention: Post-traumatic UKA (P-UKA)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Primary OA UKA (OA-UKA)
Number of subjects: 13
Study: 32561971

Group type: EXPERIMENTAL
Intervention: PET/MRI
Number of subjects: 101
Study: 32562118

Group type: EXPERIMENTAL
Intervention: Sequencing of plasma DNA
Number of subjects: 4
Study: 32562609

Group type: EXPERIMENTAL
Intervention: EUS assessment and endoscopic pancreatic function tests (ePFTs) with intravenous secretin 0.2 μg/kg
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: EUS assessment and ePFTs after secretin
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: EUS diagnosis of chronic pancreatitis (≥5 criteria)
Number of subjects: 145
Study: 32562630

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32562686

Group type: EXPERIMENTAL
Intervention: Prognostic tools including electrophysiological tests, neuroimaging, and chemical biomarkers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening for cognitive impairments, emotional problems, and fatigue
Number of subjects: 0
Study: 32563078

Group type: EXPERIMENTAL
Intervention: ESUS patients
Number of subjects: 320

Group type: COMPARATOR
Intervention: Non-ESUS patients
Number of subjects: 320
Study: 32563721

Group type: EXPERIMENTAL
Intervention: First anti-TNF therapy
Number of subjects: 1674

Group type: EXPERIMENTAL
Intervention: Non-biologic therapy augmentation
Number of subjects: 1674

Group type: EXPERIMENTAL
Intervention: IBD-related hospitalization
Number of subjects: 1674

Group type: EXPERIMENTAL
Intervention: Anti-TNF discontinuation
Number of subjects: 1674
Study: 32564074

Group type: EXPERIMENTAL
Intervention: Mp1p antigen-detecting enzyme immunoassay (EIA)
Number of subjects: 889

Group type: COMPARATOR
Intervention: Blood culture
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Paired plasma and urine testing
Number of subjects: 889
Study: 32564244

Group type: EXPERIMENTAL
Intervention: GlycA
Number of subjects: 335

Group type: COMPARATOR
Intervention: hsCRP
Number of subjects: 335
Study: 32564277

Group type: EXPERIMENTAL
Intervention: Epacadostat 25 mg or 100 mg BID
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Epacadostat 100 mg BID with pembrolizumab 200 mg every 3 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Epacadostat 25 mg BID with pembrolizumab 200 mg every 3 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Overall treatment-related adverse events
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Overall safety and tolerability of epacadostat and pembrolizumab
Number of subjects: 15
Study: 32564301

Group type: EXPERIMENTAL
Intervention: Vixotrigine 150 mg three times daily for 6 days and once on day 7
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol with vixotrigine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Levonorgestrel with vixotrigine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Vixotrigine alone
Number of subjects: 36
Study: 32564693

Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system inhibitors
Number of subjects: 1591

Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index
Number of subjects: 1591
Study: 32565447

Group type: EXPERIMENTAL
Intervention: Prehospital notification application
Number of subjects: 471
Study: 32565475

Group type: EXPERIMENTAL
Intervention: Dialectical Behaviour Therapy (DBT) skill-infused college course, consisting of 15 weekly 2.5-hour lessons, weekly homework assignments, and a final examination.
Number of subjects: 0

Group type: COMPARATOR
Intervention: University as usual (control group)
Number of subjects: 0
Study: 32567415

Group type: EXPERIMENTAL
Intervention: Dehydrated human amniotic membrane allograft (DAMA) with comprehensive care, applied weekly for 4 months
Number of subjects: 20
Study: 32567817

Group type: EXPERIMENTAL
Intervention: Osimertinib (80-mg oral dose) in patients with severe renal impairment (SRI)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Osimertinib (80-mg oral dose) in patients with normal renal function (NRF)
Number of subjects: 15
Study: 32568460

Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT-I program tailored for AYA cancer survivors
Number of subjects: 22
Study: 32568632

Group type: EXPERIMENTAL
Intervention: Biochemical nonadherence to tamoxifen (serum level < 60 ng/mL)
Number of subjects: 1177

Group type: EXPERIMENTAL
Intervention: Self-reported adherence to tamoxifen therapy
Number of subjects: 1177

Group type: EXPERIMENTAL
Intervention: Biochemical nonadherence to tamoxifen
Number of subjects: 1177
Study: 32568636

Group type: EXPERIMENTAL
Intervention: FLAIR-Hyperintense Arteries (FLAIR-HAs)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: FLAIR-HAs with Large Vessel Occlusion (LVO)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: FLAIR-HAs without Large Vessel Occlusion (LVO)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: FLAIR-HAs
Number of subjects: 293
Study: 32568652

Group type: EXPERIMENTAL
Intervention: Moderate stroke group
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Mild stroke group
Number of subjects: 135
Study: 32568654

Group type: EXPERIMENTAL
Intervention: Neuroform Atlas Stent System with adjunctive coiling
Number of subjects: 182
Study: 32568927

Group type: EXPERIMENTAL
Intervention: Toric orthokeratology lenses fitted based on elevation
Number of subjects: 25
Study: 32568958

Group type: EXPERIMENTAL
Intervention: Intravitreal and sub-Tenon's injections of bone marrow-derived stem cells
Number of subjects: 1
Study: 32569206

Group type: EXPERIMENTAL
Intervention: Pelvic peritoneum reconstruction using bladder peritoneum flap during laparoscopic ELAPE
Number of subjects: 30
Study: 32569585

Group type: EXPERIMENTAL
Intervention: Prone positioning for a minimum duration of 3 hours
Number of subjects: 56
Study: 32570392

Group type: EXPERIMENTAL
Intervention: Eye tracking data from a social information processing task in ASD group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Eye tracking data from a social information processing task in TD group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Transition between ROIs in ASD group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Objective time-dynamic measures of gaze patterns
Number of subjects: 120
Study: 32571298

Group type: EXPERIMENTAL
Intervention: Time-to-Event Continual Reassessment Method (TiTE-CRM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical model for dose-toxicity relationship
Number of subjects: 0
Study: 32571613

Group type: EXPERIMENTAL
Intervention: High-normal inflammation marker concentrations (hsCRP >0.57-9.98 mg/L, mid/upper tertile)
Number of subjects: 2192

Group type: EXPERIMENTAL
Intervention: WBC >7.0-12.4 10
Number of subjects: 2192
Study: 32571746

Group type: EXPERIMENTAL
Intervention: Precision breast IORT (PB-IORT)
Number of subjects: 204
Study: 32572189

Group type: EXPERIMENTAL
Intervention: Bosutinib 500 mg once daily
Number of subjects: 163
Study: 32572198

Group type: EXPERIMENTAL
Intervention: Deep-learning algorithm trained with image-level classification labels and anatomical/pathological labels
Number of subjects: 1772

Group type: COMPARATOR
Intervention: Deep-learning algorithm trained with only image-level classification labels
Number of subjects: 1772
Study: 32572470

Group type: EXPERIMENTAL
Intervention: DENV-1-LVHC strain 45AZ5 (low-dose group: 0.5 mL of 6.5 × 103 PFU/mL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: DENV-1-LVHC strain 45AZ5 (mid-dose group: 0.5 mL of 6.5 × 104 PFU/mL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: DENV-1-LVHC strain 45AZ5 (both doses)
Number of subjects: 12
Study: 32572560

Group type: EXPERIMENTAL
Intervention: DW-MRI
Number of subjects: 33

Group type: COMPARATOR
Intervention: FDG-PET/CT
Number of subjects: 33
Study: 32572849

Group type: EXPERIMENTAL
Intervention: ePIPAC with oxaliplatin (92 mg/m2)
Number of subjects: 20
Study: 32572853

Group type: EXPERIMENTAL
Intervention: 3D-printed patient-specific surgical plates
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional surgical plates
Number of subjects: 33
Study: 32573371

Group type: EXPERIMENTAL
Intervention: Good collateral group
Number of subjects: 74

Group type: COMPARATOR
Intervention: Poor collateral group
Number of subjects: 74
Study: 32573497

Group type: EXPERIMENTAL
Intervention: Metreleptin (recombinant leptin) for 6 months
Number of subjects: 11

Group type: COMPARATOR
Intervention: Baseline DNL
Number of subjects: 11
Study: 32573764

Group type: EXPERIMENTAL
Intervention: DHA
Number of subjects: 944

Group type: COMPARATOR
Intervention: Vitamin A + Vitamin E trace
Number of subjects: 944

Group type: COMPARATOR
Intervention: Vitamin A
Number of subjects: 944

Group type: COMPARATOR
Intervention: Optical coherence tomography
Number of subjects: 944

Group type: COMPARATOR
Intervention: Adverse events
Number of subjects: 944
Study: 32573816

Group type: EXPERIMENTAL
Intervention: Supervised outpatient exercise intervention (2 sessions per week for 8 weeks)
Number of subjects: 21
Study: 32573983

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow-derived mesenchymal stromal cells (MSC)
Number of subjects: 11
Study: 32574023

Group type: EXPERIMENTAL
Intervention: Crisaborole ointment, 2%
Number of subjects: 0
Study: 32574101

Group type: EXPERIMENTAL
Intervention: Seven-valent pneumococcal conjugate vaccine (PCV7)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pneumococcal non-typeable vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 0
Study: 32574349

Group type: EXPERIMENTAL
Intervention: AGDAS (ano-scrotal)
Number of subjects: 3705

Group type: EXPERIMENTAL
Intervention: AGDAF (ano-fourchette)
Number of subjects: 3705

Group type: EXPERIMENTAL
Intervention: AGDAP (ano-penile)
Number of subjects: 3705

Group type: EXPERIMENTAL
Intervention: AGDAC (ano-clitoral)
Number of subjects: 3705

Group type: EXPERIMENTAL
Intervention: AGD body size indices (weight, BMI, body surface area, length)
Number of subjects: 3705
Study: 32574517

Group type: EXPERIMENTAL
Intervention: Antifibrotic drugs
Number of subjects: 0
Study: 32574599

Group type: EXPERIMENTAL
Intervention: Novel monitoring device
Number of subjects: 0
Study: 32574803

Group type: EXPERIMENTAL
Intervention: fMRI-based neurofeedback (NF)
Number of subjects: 68
Study: 32575130

Group type: EXPERIMENTAL
Intervention: G-POEM (Gastric Peroral Endoscopic Myotomy)
Number of subjects: 76
Study: 32575141

Group type: EXPERIMENTAL
Intervention: Prior GDM group (413 women)
Number of subjects: 796

Group type: COMPARATOR
Intervention: Non-GDM group (383 women)
Number of subjects: 796
Study: 32575163

Group type: COMPARATOR
Intervention: Probiotics
Number of subjects: 695
Study: 32576092

Group type: EXPERIMENTAL
Intervention: Circulating Th17 and Th22 Cells
Number of subjects: 0